Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of ophthalmic diseases. It focuses on the development of products for the pharmaceutical treatment of glaucoma.

The company was founded in 2005 and is headquartered in Bridgewater, New Jersey with research facilities in Research Triangle Park, North Carolina.

Aerie Pharmaceuticals, Inc. is a former subsidiary of Duke University Medical Center.

Type
Public
HQ
Irvine, US
Founded
2005
Size (employees)
70 (est)
Aerie Pharmaceuticals was founded in 2005 and is headquartered in Irvine, US

Key People at Aerie Pharmaceuticals

Richard J. Rubino

Richard J. Rubino

Chief Financial Officer
Casey C. Kopczynski

Casey C. Kopczynski

Chief Research Officer and Co-Founder
Gerald D. Cagle

Gerald D. Cagle

COO, Cognoptix Inc.; Former SVP, Research & Development; CSO, Alcon Laboratories Inc.
Thomas A. Mitro

Thomas A. Mitro

President and Chief Operating Officer
Dennis Henner

Dennis Henner

Managing Director Clarus Ventures
Murray Goldberg

Murray Goldberg

Chief Financial Officer Regeneron Pharmaceuticals, Inc.

Aerie Pharmaceuticals Office Locations

Aerie Pharmaceuticals has offices in Irvine and Bedminster Township
Irvine, US (HQ)
1500 2030 Main St
Bedminster Township, US
15 135 Us 206

Aerie Pharmaceuticals Data and Metrics

Aerie Pharmaceuticals Financial Metrics

Numbers are in $, USD

Net income (FY, 2016)

(99.1 m)

EBIT (FY, 2016)

(96.9 m)

Market capitalization (24-May-2017)

1.4 b

Closing share price (24-May-2017)

40.8

Cash (31-Dec-2016)

197.9 m
Aerie Pharmaceuticals's current market capitalization is $1.4 b.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

R&D expense

(52.4 m)

General and administrative expense

(44.5 m)

Operating expense total

(96.9 m)

EBIT

(96.9 m)

Pre tax profit

(98.9 m)

Income tax expense

(193 k)

Net Income

(31.1 m)(48.1 m)(74.4 m)(99.1 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

69.6 m85.6 m91.1 m197.9 m

Inventories

618 k1.1 m1.9 m4 m

Current Assets

70.3 m141 m138.4 m237.7 m

Total Assets

70.5 m161.1 m159.1 m248.3 m

Accounts Payable

3.5 m551 k551 k551 k

Current Liabilities

3.5 m8.9 m17.1 m19.4 m

Additional Paid-in Capital

162 m171.3 m236.5 m422 m

Retained Earnings

(143.2 m)(217.6 m)(316.6 m)

Total Equity

67 m18.8 m105.3 m

Financial Leverage

1.1 x8.5 x2.4 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(31.1 m)(48.1 m)(74.4 m)(99.1 m)

Depreciation and Amortization

64 k73 k252 k970 k

Accounts Payable

2 m551 k

Cash From Operating Activities

(16.4 m)(33.7 m)(55.7 m)(79.8 m)

Cash From Investing Activities

(63 k)(73.3 m)9.4 m18.1 m

Cash From Financing Activities

83.2 m123 m51.8 m168.6 m

Interest Paid

2.2 m2.2 m

Income Taxes Paid

600 k1.8 m
Y, 2016

Financial Leverage

2.4 x

Aerie Pharmaceuticals Market Value History

Aerie Pharmaceuticals Company Life and Culture

You may also be interested in